USP32 is highly expressed in gastric cancer and is closely related to the stage and prognosis of gastric cancer patients. Downregulation of USP32 significantly reduces SMAD2 expression, thereby inhibiting the proliferation, migration, and resistance to cisplatin of gastric cancer cells.906. Here, SMAD2 is linked to gastric cancer.